Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.55 |
| ▸ | TK2 | O00142 | 4/20 | 0.51 |
| ▸ | CDA | P32320 | 1/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080899 | 0.91 | PYGM (0.44) | PYGMTK2LMNASMN1; SMN2 | |
| SCHEMBL3084982 | 0.90 | PYGM (0.68) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3080113 | 0.90 | PYGM (0.68) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL4952189 | 0.85 | PYGM (0.56) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL720545 | 0.83 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL368853 | 0.83 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL12642313 | 0.83 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL4601745 | 0.83 | PYGM (0.77) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL23590367 | 0.82 | LMNA (0.59) | PYGMTK2CDASLC28A1SLC28A2 | |
| SCHEMBL10888417 | 0.82 | LMNA (0.59) | PYGMTK2CDASLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054406-B1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | PYGM 1888/4885TK2 34/4885CDA 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.